Inhibition of Lactate Dehydrogenase Activity as an Approach to Cancer Therapy

Citations Over TimeTop 10% of 2014 papers

Abstract

In the attempt of developing innovative anticancer treatments, growing interest has recently focused on the peculiar metabolic properties of cancer cells. In this context, LDH, which converts pyruvate to lactate at the end of glycolysis, is emerging as one of the most interesting molecular targets for the development of new inhibitors. In fact, because LDH activity is not needed for pyruvate metabolism through the TCA cycle, inhibitors of this enzyme should spare glucose metabolism of normal non-proliferating cells, which usually completely degrade the glucose molecule to CO2. This review is aimed at summarizing the available data on LDH biology in normal and neoplastic cells, which support the anticancer therapeutic approach based on LDH inhibition. These data encouraged pharmaceutical industries and academic institutions in the search of small-molecule inhibitors and promising candidates have recently been identified. The availability of inhibitors with drug-like properties will allow the evaluation in the near future of the real potential of LDH inhibition in anticancer treatment, also making the identification of the most responsive neoplastic conditions possible.

Related Papers

• → Diagnostic Value of Lactate Dehydrogenase Isoenzyme Pattern in Pleural Effusions(1997)14 cited
• → Lactate Dehydrogenase in Tears(1980)9 cited
• → [Expression of lactate dehydrogenase-5 in non-Hodgkin lymphoma and its clinical significance].(2016)1 cited
• → Evidence for the existence of lactate dehydrogenase N in embryonic chick liver(1973)2 cited
• → Evaluation of Serum Levels of Lactate Dehydrogenase Isoenzymes in COVID- 19 Patients(2021)